T. Rowe Price (IMCR) holds 1.89M ADRs, files Schedule 13G/A amendment
Rhea-AI Filing Summary
T. Rowe Price Investment Management, Inc. filed an amendment to a Schedule 13G reporting beneficial ownership of 1,891,600 ADRs of Immunocore Holdings plc, representing 3.7% of the class. The filing lists sole voting and dispositive power over the reported shares and includes a signed declaration dated 05/15/2026.
The filing affirms ownership is 5% or less and contains a customary denial that the filer is the beneficial owner. No transaction details or purchase/sale directions are reported in this excerpt.
Positive
- None.
Negative
- None.
Insights
Large asset manager reports a passive stake below the 5% reporting threshold.
The amendment lists 1,891,600 ADRs (3.7%) with sole voting and dispositive power, consistent with an institutional position reported on Schedule 13G. The filing's language and the 5% or less statement indicate passive investment status rather than an active control intent.
Holder decisions will determine future disclosure; subsequent amendments would appear if ownership crosses regulatory thresholds or the filer changes intent.
Key Figures
Key Terms
Schedule 13G/A regulatory
beneficial ownership financial
sole dispositive power regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.